FierceBiotechOriginal article
{"a":[{"_":"‘We are proud to be in the lead’: Vaderis lands $152M for phase 3 study in rare blood vessel disorder","$":{"href":"/biotech/vaderis-lands-152m-squeeze-akt-inhibitor-through-phase-3-and-regulatory-approval","hreflang":"en"}}]}
Positive
AI Analysis
Summary
Vaderis Therapeutics secured an oversubscribed $152 million Series B financing to advance its AKT inhibitor through Phase 3 development for a rare blood vessel disorder, targeting regulatory approval and market launch.
Clinical Trial Data
Phase
Phase 3
Importance:6/10
Sentiment:
0.70
financingseries BAKT inhibitorrare diseasephase 3
Read the original article
Published by FierceBiotech on August 10, 2026 1:45 PM
